Very excited to see this study out in Journal of Hepatology. We used the high-fidelity PspCas13b to silence HBV doi.org/10.1016/j.jhep…. A great collaboration between our lab Peter Mac Cancer Centre Peter Mac Research and Peter Revill lab and others Doherty Institute #CRISPR #HBV

I am looking for a post-doc to work on our ⁦MBIE Science⁩ project on #phages for #biocontrol #microbiology #genomics #genetics ⁦Microbiology and Immunology Otago⁩ ⁦University of Otago⁩ pls repost otago.taleo.net/careersection/…

Our Department of Microbiology and Immunology ⁦Microbiology and Immunology Otago⁩ University of Otago is recruiting a new Lecturer / Senior Lecturer / Associate Professor - Microbiology (2401357). Please share with your networks. otago.taleo.net/careersection/…

Very exciting to see this fantastic work published by Joo_Lab. Congratulations to Ivo Severins, Carolien Bastiaanssen and the rest of the team Joo_Lab on this amazing work 👏

Feels great to spend the evening dinning with these amazing people from our lab and celebrate their achievements...I am so lucky to be part of this incredible journey with you all

This is a great opportunity to help developing cutting-edge cancer immunotherpies in an outstanding research environment

💥 Research Fellow opportunity in our group University of Melbourne to develop #bioinformatics pipelines and platforms for cutting-edge 🧬 therapeutics for infectious diseases. Come and join our team👨🏻‍💻! Collab with Doherty Institute and @FarehLab at Peter Mac Cancer Centre

🧬 World-First Breakthrough! Peter Mac scientists use CRISPR to silence cancer-causing mutations like KRAS, NRAS & BRAF, driving aggressive cancers. This precise method spares healthy genes, offering new hope for personalised treatments. Read more: petermac.org/about-us/news-…

Very excited to share our latest preprint describing systematic silencing of oncogenic fusion transcripts with CRISPR-Cas13. This approach is highly efficient against drug-resistant and undruggable fusions. Led by the fantastic Dr. Hu Peter Mac Research biorxiv.org/content/10.110…

After leukemia treatments failed, Alyssa Tapley, at age 13, was told she would die. Then, doctors tried an experimental gene-edited therapy. She became the first human to try the treatment made possible by U.S. federal funding. Now 16, she’s cancer-free and planning her future.

Alyssa Tapley was 13 when doctors told her she was going to die. She was diagnosed with a rare form of leukemia and had endured a year of failed treatments, including chemotherapy and a bone marrow transplant, when her doctors said they had run out of options. They were talking